Free Trial
OTCMKTS:DSNKY

Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

Daiichi Sankyo logo
$28.90 -0.67 (-2.27%)
(As of 11/20/2024 ET)

About Daiichi Sankyo Stock (OTCMKTS:DSNKY)

Key Stats

Today's Range
$28.76
$29.00
50-Day Range
$28.90
$36.40
52-Week Range
$26.16
$42.48
Volume
99,715 shs
Average Volume
114,719 shs
Market Capitalization
N/A
P/E Ratio
0.25
Dividend Yield
77.75%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Daiichi Sankyo Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
16th Percentile Overall Score

DSNKY MarketRank™: 

Daiichi Sankyo scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Daiichi Sankyo.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Daiichi Sankyo is 0.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.26.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Daiichi Sankyo is 0.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.86.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Daiichi Sankyo has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Daiichi Sankyo has recently increased by 4,266.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Daiichi Sankyo pays a meaningful dividend of 3.12%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Daiichi Sankyo does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Daiichi Sankyo is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Daiichi Sankyo's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Daiichi Sankyo has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Daiichi Sankyo has recently increased by 4,266.67%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Daiichi Sankyo has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Daiichi Sankyo this week, compared to 0 articles on an average week.
Receive DSNKY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter.

DSNKY Stock News Headlines

Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
AstraZeneca, Daiichi Sankyo sumbit new BLA for datopotamab deruxtecan
See More Headlines

DSNKY Stock Analysis - Frequently Asked Questions

Daiichi Sankyo's stock was trading at $27.35 on January 1st, 2024. Since then, DSNKY shares have increased by 5.7% and is now trading at $28.90.
View the best growth stocks for 2024 here
.

Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:DSNKY
CIK
N/A
Fax
N/A
Employees
17,435
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:DSNKY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners